FI92557C - Menetelmä pastöroidun immunoglobuliinivalmisteen valmistamiseksi - Google Patents
Menetelmä pastöroidun immunoglobuliinivalmisteen valmistamiseksi Download PDFInfo
- Publication number
- FI92557C FI92557C FI872578A FI872578A FI92557C FI 92557 C FI92557 C FI 92557C FI 872578 A FI872578 A FI 872578A FI 872578 A FI872578 A FI 872578A FI 92557 C FI92557 C FI 92557C
- Authority
- FI
- Finland
- Prior art keywords
- immunoglobulin
- solution
- carboxylic acid
- heated
- process according
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 49
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 28
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 11
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 238000009928 pasteurization Methods 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 13
- 241000700605 Viruses Species 0.000 abstract description 8
- 244000052769 pathogen Species 0.000 abstract description 4
- 241000598436 Human T-cell lymphotropic virus Species 0.000 abstract description 2
- 208000006454 hepatitis Diseases 0.000 abstract description 2
- 231100000283 hepatitis Toxicity 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 238000010438 heat treatment Methods 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 5
- 239000012267 brine Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000005686 Serum Globulins Human genes 0.000 description 2
- 108010045362 Serum Globulins Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010032597 Cohn fraction II Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000003171 anti-complementary effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940010675 intramuscular immunoglobulin Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3619565 | 1986-06-11 | ||
| DE19863619565 DE3619565A1 (de) | 1986-06-11 | 1986-06-11 | Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI872578A0 FI872578A0 (fi) | 1987-06-09 |
| FI872578L FI872578L (fi) | 1987-12-12 |
| FI92557B FI92557B (fi) | 1994-08-31 |
| FI92557C true FI92557C (fi) | 1997-12-02 |
Family
ID=6302735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI872578A FI92557C (fi) | 1986-06-11 | 1987-06-09 | Menetelmä pastöroidun immunoglobuliinivalmisteen valmistamiseksi |
Country Status (10)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4762714A (en) * | 1986-04-08 | 1988-08-09 | Miles Laboratories, Inc. | Preparation of retrovirus-free immunoglobulins |
| JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| DE4344824C1 (de) * | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| JP6681711B2 (ja) | 2012-05-14 | 2020-04-15 | ノヴォ ノルディスク アー／エス | 安定化されたタンパク質溶液 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5840532B2 (ja) * | 1975-04-08 | 1983-09-06 | カブシキガイシヤ ミドリジユウジ | Ｉｇａ オヨビ ｉｇｍ ノネツアンテイカホウ |
| EP0035204B2 (en) * | 1980-03-05 | 1991-05-22 | Miles Inc. | Pasteurized therapeutically active protein compositions |
| JPS57140724A (en) * | 1981-02-25 | 1982-08-31 | Green Cross Corp:The | Heat-treatment of aqueous solution containing cold insoluble globulin |
| DE3473407D1 (en) * | 1983-05-02 | 1988-09-22 | Immuno Ag | Method of inactivating pathogens |
| DE3330770A1 (de) * | 1983-08-26 | 1985-03-14 | Behringwerke Ag, 3550 Marburg | Verfahren zur pasteurisierung von humanplasma |
| JPH0669961B2 (ja) * | 1984-09-25 | 1994-09-07 | 株式会社ミドリ十字 | 免疫グロブリンの加熱処理方法 |
| JPH0825902B2 (ja) * | 1985-02-21 | 1996-03-13 | 株式会社ミドリ十字 | γ−グロブリンの加熱処理方法 |
| JPH0825903B2 (ja) * | 1985-05-16 | 1996-03-13 | 株式会社ミドリ十字 | γ―グロブリン含有水溶液 |
| IL86417A (en) * | 1987-05-22 | 1992-09-06 | Armour Pharma | Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers |
-
1986
- 1986-06-11 DE DE19863619565 patent/DE3619565A1/de not_active Withdrawn
-
1987
- 1987-06-05 ES ES87108170T patent/ES2059323T3/es not_active Expired - Lifetime
- 1987-06-05 AT AT87108170T patent/ATE95067T1/de not_active IP Right Cessation
- 1987-06-05 DE DE87108170T patent/DE3787569D1/de not_active Revoked
- 1987-06-05 EP EP87108170A patent/EP0249167B1/de not_active Revoked
- 1987-06-09 PT PT85052A patent/PT85052B/pt active IP Right Revival
- 1987-06-09 FI FI872578A patent/FI92557C/fi not_active IP Right Cessation
- 1987-06-10 CA CA000539495A patent/CA1340737C/en not_active Expired - Lifetime
- 1987-06-10 DK DK296387A patent/DK296387A/da not_active Application Discontinuation
- 1987-06-10 AU AU74087/87A patent/AU598268B2/en not_active Ceased
- 1987-06-10 JP JP62143449A patent/JPS62292731A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| EP0249167B1 (de) | 1993-09-29 |
| DE3787569D1 (de) | 1993-11-04 |
| CA1340737C (en) | 1999-09-14 |
| PT85052B (pt) | 1990-03-08 |
| DK296387D0 (da) | 1987-06-10 |
| DE3619565A1 (de) | 1987-12-17 |
| AU598268B2 (en) | 1990-06-21 |
| PT85052A (de) | 1987-07-01 |
| FI872578L (fi) | 1987-12-12 |
| AU7408787A (en) | 1987-12-17 |
| FI92557B (fi) | 1994-08-31 |
| JPS62292731A (ja) | 1987-12-19 |
| FI872578A0 (fi) | 1987-06-09 |
| JPH0525862B2 (enrdf_load_stackoverflow) | 1993-04-14 |
| EP0249167A2 (de) | 1987-12-16 |
| EP0249167A3 (en) | 1989-05-10 |
| DK296387A (da) | 1987-12-12 |
| ATE95067T1 (de) | 1993-10-15 |
| ES2059323T3 (es) | 1994-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0196761B1 (en) | Method of virus-inactivating heat treatment of gamma-globulin | |
| US4446134A (en) | Process for heat treatment of aqueous solution containing human blood coagulation factor VIII | |
| US4764369A (en) | Undenatured virus-free biologically active protein derivatives | |
| US4540573A (en) | Undenatured virus-free biologically active protein derivatives | |
| EP0696595A1 (en) | Low temperature albumin fractionation using sodium caprylate as a partitioning agent | |
| SK287633B6 (sk) | Spôsob výroby humánneho gamaglobulínu G a humánny gamaglobulín G s inaktivovanými vírusmi | |
| JP2002275090A (ja) | 安定化蛋白質調製物およびその調製方法 | |
| RU2008916C1 (ru) | Способ пастеризации водного раствора иммуноглобулина | |
| FI107122B (fi) | Menetelmä virusten suhteen inaktivoitujen immunoglobuliiniliuosten valmistamiseksi | |
| FI92557C (fi) | Menetelmä pastöroidun immunoglobuliinivalmisteen valmistamiseksi | |
| JP2605102B2 (ja) | ウイルスおよびバクテリア汚染物の熱的不活性化中の生物学的および製薬的生成物の安定化 | |
| EP3135687B1 (en) | Method for the preparation of immunoglobulins | |
| US5116950A (en) | Process for heat treating fibrinogen | |
| US5248767A (en) | Process for the preparation of a pasteurized immunoglobulin preparation using ethanol | |
| JPS61194035A (ja) | γ−グロブリン製剤 | |
| KR101146946B1 (ko) | 알부민 제제의 제조 방법 | |
| US6338849B1 (en) | Process of preparing immunoglobulin for intravenous injection by viruses double-sterilized without adding any protectant | |
| CA2943328C (en) | Method for the preparation of immunoglobulins | |
| AU2016231646A1 (en) | Method for the preparation of immunoglobulins | |
| JP6370853B2 (ja) | 免疫グロブリンの調製方法 | |
| KR102372105B1 (ko) | 면역글로블린의 제조방법 | |
| TWI712612B (zh) | 製備免疫球蛋白溶液的方法 | |
| JPS62195331A (ja) | 血液凝固第８因子製剤の製法 | |
| AU717541B2 (en) | Inactivation of viruses by incubation with caprylate | |
| NZ724670A (en) | Method for the preparation of immunoglobulins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| GB | Transfer or assigment of application |
Owner name: CENTEON PHARMA GMBH |
|
| FG | Patent granted |
Owner name: AVENTIS BEHRING GMBH |
|
| PC | Transfer of assignment of patent |
Owner name: ZLB BEHRING GMBH |
|
| MA | Patent expired |